TARS Tarsus Pharmaceuticals

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.

Participants may access the webcast . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
 
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223





EN
28/10/2025

Underlying

TARSTarsus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tarsus Pharmaceuticals

 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Participate in Upcoming Investor Conference

Tarsus to Participate in Upcoming Investor Conference IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11th, at 11:30 a.m. PT / 2:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus . Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Ta...

23h / 29m 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Reports Third Quarter 2025 Financial Results and Recent Busines...

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the third quarter ended September 30, 2025. “Our third qua...

November 4, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, Nove...

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update. Participants may access the webcast . A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceut...

October 28, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus to Participate in Upcoming Investor Conferences

Tarsus to Participate in Upcoming Investor Conferences IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th Annual Healthcare Conference on Wednesday, September 3rd, at 6:30 a.m. PT / 9:30 a.m. ETH.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus . Replays will be available ...

August 27, 2025 1 EN
 PRESS RELEASE
Free
TARS Tarsus Pharmace...

Tarsus Reports Second Quarter 2025 Financial Results and Recent Busine...

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions Pipeline advancements and global efforts remain on track Management to host conference call today, August 6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch